Edwards Lifesciences (NYSE:EW) Releases Q2 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) updated its second quarter 2026 earnings guidance on Thursday. The company provided EPS guidance of 0.700-0.760 for the period, compared to the consensus EPS estimate of 0.750. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Edwards Lifesciences also updated its FY 2026 guidance to 2.950-3.050 EPS.

Analyst Ratings Changes

A number of brokerages have weighed in on EW. Piper Sandler reissued an “overweight” rating and set a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Robert W. Baird set a $90.00 price target on Edwards Lifesciences in a research note on Monday, January 12th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday. Barclays restated an “overweight” rating and set a $104.00 price objective (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. Finally, Stifel Nicolaus set a $110.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a report on Tuesday, January 20th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.74.

Edwards Lifesciences Stock Down 2.3%

Shares of Edwards Lifesciences stock traded down $1.84 during trading hours on Thursday, hitting $79.69. 6,181,177 shares of the company’s stock traded hands, compared to its average volume of 4,688,717. The stock has a 50 day simple moving average of $81.47 and a 200-day simple moving average of $82.17. The company has a quick ratio of 3.09, a current ratio of 3.72 and a debt-to-equity ratio of 0.06. The company has a market cap of $45.95 billion, a PE ratio of 43.55, a PEG ratio of 2.08 and a beta of 0.95. Edwards Lifesciences has a twelve month low of $72.30 and a twelve month high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts anticipate that Edwards Lifesciences will post 2.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $80.98, for a total value of $82,518.62. Following the transaction, the vice president owned 33,934 shares of the company’s stock, valued at $2,747,975.32. This trade represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the completion of the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at $3,177,507.96. This represents a 24.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 86,058 shares of company stock valued at $7,118,636 over the last quarter. Insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Hedge funds have recently made changes to their positions in the business. Brighton Jones LLC bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $266,000. Vinva Investment Management Ltd bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $279,000. Kovack Advisors Inc. bought a new stake in shares of Edwards Lifesciences during the fourth quarter valued at approximately $245,000. L2 Asset Management LLC raised its holdings in shares of Edwards Lifesciences by 11.8% during the third quarter. L2 Asset Management LLC now owns 2,923 shares of the medical research company’s stock valued at $227,000 after buying an additional 309 shares during the last quarter. Finally, Zions Bancorporation National Association UT raised its holdings in shares of Edwards Lifesciences by 114.8% during the fourth quarter. Zions Bancorporation National Association UT now owns 2,099 shares of the medical research company’s stock valued at $179,000 after buying an additional 1,122 shares during the last quarter. Institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.